Pulmonary redox imbalance drives early fibroproliferative response in moderate/severe coronavirus disease-19 acute respiratory distress syndrome and impacts long-term lung abnormalities

Background COVID-19-associated pulmonary fibrosis remains frequent. This study aimed to investigate pulmonary redox balance in COVID-19 ARDS patients and possible relationship with pulmonary fibrosis and long-term lung abnormalities. Methods Baseline data, chest CT fibrosis scores, N-terminal peptid...

Full description

Saved in:
Bibliographic Details
Published in:Annals of intensive care 2024-05, Vol.14 (1), p.72-72, Article 72
Main Authors: Yang, Chun, Tan, Yuanyuan, Li, Zihao, Hu, Lei, Chen, Yuanyuan, Zhu, Shouliang, Hu, Jiawei, Huai, Tingting, Li, Mingqing, Zhang, Guobin, Rao, Dewang, Fei, Guanghe, Shao, Min, Ding, Zhenxing
Format: Article
Language:English
Subjects:
Acute respiratory distress syndrome
Anesthesiology
COVID-19
Critical Care Medicine
Emergency Medicine
Intensive
Long COVID
Lung diseases
Medicine
Medicine & Public Health
Oxidative stress
Pulmonary fibrosis
Recovery (Medical)
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background COVID-19-associated pulmonary fibrosis remains frequent. This study aimed to investigate pulmonary redox balance in COVID-19 ARDS patients and possible relationship with pulmonary fibrosis and long-term lung abnormalities. Methods Baseline data, chest CT fibrosis scores, N-terminal peptide of alveolar collagen III (NT-PCP-III), transforming growth factor (TGF)-β1, superoxide dismutase (SOD), reduced glutathione (GSH), oxidized glutathione (GSSG) and malondialdehyde (MDA) in bronchoalveolar lavage fluid (BALF) were first collected and compared between SARS-CoV-2 RNA positive patients with moderate to severe ARDS (n = 65, COVID-19 ARDS) and SARS-CoV-2 RNA negative non-ARDS patients requiring mechanical ventilation (n = 63, non-ARDS). Then, correlations between fibroproliferative (NT-PCP-III and TGF-β1) and redox markers were analyzed within COVID-19 ARDS group, and comparisons between survivor and non-survivor subgroups were performed. Finally, follow-up of COVID-19 ARDS survivors was performed to analyze the relationship between pulmonary abnormalities, fibroproliferative and redox markers 3 months after discharge. Results Compared with non-ARDS group, COVID-19 ARDS group had significantly elevated chest CT fibrosis scores (p 
ISSN:2110-5820
2110-5820
DOI:10.1186/s13613-024-01293-3